TQ Therapeutics completed the acquisition of Juno Therapeutics from Bristol Myers-backed Juno Therapeutics.

TQ Therapeutics, a pharmaceutical company, completed the acquisition of Juno Therapeutics, the German subsidiary of Juno Therapeutics, from Bristol Myers-backed Juno Therapeutics, a biopharma company. Financial terms were not disclosed. “This acquisition presents an incredible opportunity for us to continue development of our breakthrough ultra-short extracorporeal cell and gene therapy approach to create treatments of the future. This strategic transaction reinforces our commitment to making cell and gene therapy broadly accessible to address the medical needs of many patients,” Dr. Christian Eckert, TQ Therapeutics CEO.